mesoblast


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

mesoblast

 [mez´o-blast]
the mesoderm, especially in the early stages.

mes·o·blast

(mez'ō-blast),
Mesoderm, especially in the early undifferentiated stages.
See also: mesoderm.
[meso- + G. blastos, germ]

mesoblast

/meso·blast/ (mez´o-blast) mesoderm, especially in the early, undifferentiated stages.

mesoblast

(mĕz′ə-blăst′, mĕs′-)
n.
The middle germinal layer of an early embryo, consisting of undifferentiated cells destined to become the mesoderm.

mes′o·blas′tic adj.

mesoblast

(1) Mesoderm [[NE3]]. 
(2) The middle germ layer of an early embryo, which consists of stem cells that give rise to the mesoderm and develop into muscle, bone, cartilage, blood cells and connective tissue.

mes·o·derm

(mez'ō-dĕrm)
The middle of the three primary germ layers of the embryo (the others being ectoderm and endoderm); mesoderm is the origin of all connective tissues, all musculature, blood, cardiovascular and lymphatic systems, most of the urogenital system, and the lining of the pericardial, pleural, and peritoneal cavities.
Synonym(s): mesoblast.
[G. meso- middle + G. derma, skin]

mesoblast

the mesoderm, especially in the early stages.
References in periodicals archive ?
Reducing the severity of a patient's heart failure "would give them back potentially many years of good quality life," said Mesoblast CEO Silviu Itescu.
The report reviews current pipeline of Mesoblast Limited's human therapeutic division and enlists all their major and minor projects
Mesoblast selected Rave for its superior user experience and comprehensive functionality.
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Angioblast and Mesoblast are conducting a Pilot Clinical Trial in Australia focused on the treatment of up to 10 patients suffering from severe coronary artery disease and heart muscle damage.
Under the agreement, Osiris continues to provide services to Mesoblast to ensure a smooth transition.
Mesoblast will pay Osiris US$20 million upon closing of the transaction, with US$15 million in Mesoblast stock payable upon transfer of the assigned assets.
Mesoblast can now supply MPCs manufactured in Singapore, in addition to those manufactured at its US facility.
I am proud to report the progress we've made over the past year at Mesoblast.
In December 2016, Mesoblast and Mallinckrodt Pharmaceuticals agreed to exclusively negotiate a commercial and development partnership for MPC-06-ID in the treatment of chronic low back pain due to disc degeneration.